Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates.   “The past quarter has continued to be transformative for the company as we completed a key financing expected to provide runway through three trial readouts, including our ongoing Phase 3 trial in platinum resistant/refractory ovarian cancer,” said Thomas Zindrick, President, Chairman and CEO of Genelux. “Beyond our pivotal Phase 3 trial, we look to provide interim data for systemic delivery of Olvi-Vec in both small and non-small cell lung cancer in the next 12 months.” The Company anticipates announcing interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025, with interim data from our Phase 1b trial in recurrent small cell lung cancer expected later this year. Both trials involve the intravenous administration of Olvi-Vec and the re-challenging of patients who have previously failed platinum-based chemotherapy. These designs are based on a prior clinical trial that demonstrated the benefits of intravenously administered Olvi-Vec in patients with lung disease (either primary or metastatic), as well as on our Phase 2 data in platinum-resistant/refractory ovarian cancer (PRROC). Pipeline Highlights The ongoing Phase 3 OnPrime/GOG-3076 registrational trial in PRROC continues to enroll patients with over 23 sites activated (NCT05281471). The Company anticipates topline results in the second half of 2025. The United States based Phase 2 trial in recurrent non-small cell lung cancer (NSCLC) is expected to report interim results in mid-2025. The Company anticipates an interim readout in the second half of 2024 for the Phase 1b part of the Phase 1b/2 trial in patients with recurrent small cell lung cancer in China. Both trials leverage Olvi-Vec via systemic administration, unlocking Olvi-Vec’s potential to be the first Phase 3 systemic oncolytic vaccinia virus. Business Updates In May 2024, the Company completed an underwritten public offering of its common stock and accompanying warrants. The total gross proceeds of the offering were $30.0 million USD and the Company raised $27.7 million USD in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company. The net proceeds from the offering are expected to provide working capital into the first quarter of 2026 for general corporate purposes, including the continued clinical development of Olvi-Vec. Second Quarter 2024 Financial Results Cash, cash equivalents, short and long-term investments were $40.4 million as of June 30, 2024. The Company expects its existing cash, cash equivalents, short and long-term investments will provide runway into the first quarter of 2026. Research and development (R&D) expenses were $4.4 million for the second quarter of 2024, as compared to $2.9 million for the second quarter 2023, respectively. The $1.5 million year-over-year increase in R&D expenses in 2024 was primarily due to a $0.7 million increase in clinical and regulatory expenses associated with the Company’s Phase 3 On Prime registration trial, a $0.4 million increase in outsourced manufacturing services, a $0.3 million increase in employee compensation and related expenses in 2024 and a $0.3 million increase in stock-related compensation in 2024 offset by decreases in other R&D expenses of $0.2 million. General and administrative (G&A) expenses were flat year-over year at $2.5 million in the second quarter of 2024 and 2023. A year-over-year increase of $0.4 million in stock compensation in 2024 was offset by a decrease of $0.5 million in professional service expenses, primarily from a decrease in corporate legal costs in 2024. Net loss was $6.6 million for the second quarter of 2024 or a net loss per share of $0.22, as compared to net loss of $5.8 million for the second quarter of 2023, or a net loss per share of $0.23. About Genelux Corporation Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux’s discovery and development efforts revolves around its’ proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn. Forward-Looking Statements This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “believes,” “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to Genelux’s future plans and prospects, Genelux’s anticipated cash runway and the sufficiency of its resources to support its planned operations, the planned timing of Genelux’s data results in its ongoing clinical trials and continued development of Olvi-Vec, and the potential capabilities and advantages of Olvi-Vec. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Genelux’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Genelux does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. Investor and Media Contacts Ankit Bhargava, MDAllele Communications, [email protected] Source: Genelux Corporation    Genelux CorporationCondensed Balance Sheets(in thousands, except for share amounts and par value data)    June 30,December 31,  2024  2023 ASSETS(Unaudited) Current Assets  Cash and cash equivalents$7,858 $9,418 Short-term investments 25,778  13,773 Prepaid expenses and other current assets 1,234  1,012 Total Current Assets 34,870  24,203    Property and equipment, net 1,306  1,170 Right of use assets 2,098  2,428 Long-term investments 6,813  – Other assets 92  92 Total Other Assets 10,309  3,690    TOTAL ASSETS$45,179 $27,893    LIABILITIES AND SHAREHOLDERS’ EQUITY  Current Liabilities  Accounts payable and accrued expenses$4,786 $3,784 Accrued payroll and payroll taxes 517  2,117 Lease liabilities, current portion 500  653 Total Current Liabilities 5,803  6,554    Lease liabilities, long-term portion 1,707  1,866 Total Liabilities 7,510  8,420    Shareholders’ Equity  Preferred stock, par value $0.001, 10,000,000 shares authorized;  no shares issued and outstanding, respectively; –  – Common stock, par value $0.001, 200,000,000 shares authorized;  34,512,642 and 26,788,986 shares issued and outstanding, respectively 35  27 Treasury stock, 433,333 shares, at cost (433) (433)Additional paid-in capital 274,028  241,389 Accumulated other comprehensive income (loss) (11) 14 Accumulated deficit (235,950) (221,524)Total Shareholders’ Equity 37,669  19,473    TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$45,179 $27,893    The accompanying notes are an integral part of these condensed financial statements.          Genelux CorporationCondensed Statements of Operations(in thousands, except for share amounts and per share data)             Three Months Ended Six Months Ended June 30, June 30,  2024  2023   2024  2023  (Unaudited) (Unaudited)      Revenues$- $-  $8 $170       Operating expenses:     Research and development 4,417  2,943   8,427  5,788 General and administrative 2,475  2,452   6,588  6,239 Total operating expenses 6,892  5,395   15,015  12,027       Loss from operations (6,892) (5,395)  (15,007) (11,857)      Other income (expenses):     Interest income 316  –   581  – Interest expense –  (24)  –  (167)Debt discount amortization –  –   –  (649)Financing costs –  –   –  (3,110)Debt extinguishment costs  (402)   (402)Total other income (expenses), net 316  (426)  581  (4,328)      NET LOSS$(6,576)$(5,821) $(14,426)$(16,185)      LOSS PER COMMON SHARE – BASIC AND DILUTED$(0.22)$(0.23) $(0.51)$(0.72)      WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING –    BASIC AND DILUTED 29,689,344  25,068,334   28,308,046  22,334,311       The accompanying notes are an integral part of these condensed financial statements.      Genelux CorporationCondensed Statements of Comprehensive Loss(in thousands)       Three Months Ended Six Months Ended June 30, June 30,  2024  2023   2024  2023  (Unaudited) (Unaudited)      Net loss$(6,576)$(5,821) $(14,426)$(16,185)      Other comprehensive loss:     Net unrealized loss on short and long-term investments (6) –   (25) – Comprehensive loss$(6,582)$(5,821) $(14,451)$(16,185)            The accompanying notes are an integral part of these condensed financial statements.